Edgewise Therapeutics Announces 2025 Priorities, Progress In Muscular Dystrophy And Cardiac Therapies; Seeks Completion Of GRAND CANYON Recruitment For Becker Trials In Q1; Targets Phase 2 FDA Feedback On CANYON In H1; Plans Phase 3 For Duchenne

BenzingaJan 13 08:49 ET

Express News | Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

ReutersJan 13 08:00 ET

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Edgewise Therapeutics (EWTX) and Avadel Pharmaceuticals (AVDL)

TipRanksJan 13 01:00 ET · Ratings

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Yahoo FinanceJan 7 08:00 ET

Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

Simply Wall StJan 3 07:30 ET

Insider Sale: Chief Scientific Officer of $EWTX (EWTX) Sells 100,000 Shares

Quiver QuantitativeDec 31 17:16 ET